Recent Quotes (30 days)

You have no recent quotes
chg | %

Microbix Biosystems Inc  

(Public, TSE:MBX)   Watch this stock  
Find more results for MBX
-0.010 (-3.33%)
Nov 27 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.28 - 0.30
52 week 0.28 - 0.88
Open 0.29
Vol / Avg. 54,140.00/30,585.00
Mkt cap 24.56M
P/E     -
Div/yield     -
EPS 0.00
Shares 84.70M
Beta -0.95
Inst. own     -

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 3.70% 2.01%
Operating margin 6.66% 5.66%
EBITD margin - 20.05%
Return on average assets 1.49% 1.10%
Return on average equity 2.53% 2.17%
Employees 20 -
CDP Score - -


265 Watline Ave
+1-905-3618910 (Phone)
+1-905-3618911 (Fax)

Website links


Microbix Biosystems Inc is a Canada-based Company engaged in developing biological products and technologies. The Company developed a pipeline of selected biological technologies including Virusmax (Influenza Virus Yield Enhancement Technology), LumiSort (Semen Sexing Technology) and the thrombolytic drug, Kinlytic (Urokinase). The Company specializes in developing biological technologies, which leads to the development of a pipeline of products in three areas biotherapeutics, vaccines and non-therapeutic biologics. The Company’s product categories include Infectious Disease Antigens, Proficiency Testing and Adenovirus Vectors. The Virology business develops, manufactures and distributes infectious disease antigens for the medical diagnostic and vaccine research industries. The Company has commercialized approximately 60 products derived from infectious pathogens cultured and processed at its facilities.

Officers and directors

William J. Gastle Executive Chairman of the Board
Vaughn C. Embro-Pantalony President, Chief Executive Officer, Director
Charles S. Wallace Chief Financial Officer
Peter M. Blecher Independent Director
Mark A. Cochran Independent Director
Cameron L Groome Independent Director
Martin A. Marino Independent Director
Andrew Christopher Pollock Independent Director